Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: A narrative review

por Elizarova, Svetlana, Galstyan, Gagik R, Wolffenbuttel, Bruce HR
Publicado 2014

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

por Skolnik, Neil, Del Prato, Stefano, Blonde, Lawrence, Galstyan, Gagik, Rosenstock, Julio
Publicado 2021

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

por McCrimmon, Rory J., Cheng, Alice Y.Y., Galstyan, Gagik, Djaballah, Khier, Li, Xuan, Coudert, Mathieu, Frias, Juan P.
Publicado 2022

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

por Galstyan, Gagik R., Tirosh, Amir, Vargas-Uricoechea, Hernando, Mabunay, Maria Aileen, Coudert, Mathieu, Naqvi, Mubarak, Pilorget, Valerie, Khan, Niaz
Publicado 2022

Self-Treated Hypoglycemia in Type 2 Diabetes Mellitus: Results from the Second Wave of an International Cross-Sectional Survey

por Brod, Meryl, Galstyan, Gagik, Unnikrishnan, Ambika Gopalakrishnan, Harman-Boehm, Ilana, Prusty, Vinay, Lavalle, Fernando, McGill, Margaret, Murphy, Angela, Puchulu, Felix
Publicado 2016

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysi...

por Ahrén, Bo, Galstyan, Gagik, Gautier, Jean-Francois, Giorgino, Francesco, Gomez-Peralta, Fernando, Krebs, Michael, Nikonova, Elena, Stager, William, Vargas-Uricoechea, Hernando
Publicado 2016

Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa

por Giorgino, Francesco, Bhana, Sindeep, Czupryniak, Leszek, Dagdelen, Selcuk, Galstyan, Gagik R., Janež, Andrej, Lalić, Nebojsa, Nouri, Nassim, Rahelić, Dario, Stoian, Anca Pantea, Raz, Itamar
Publicado 2021

Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies

por Pedersen‐Bjergaard, Ulrik, Alsifri, Saud, Aronson, Ronnie, Berković, Maja Cigrovski, Galstyan, Gagik, Gydesen, Helge, Lekdorf, Jesper Barner, Ludvik, Bernhard, Moberg, Erik, Ramachandran, Ambady, Khunti, Kamlesh
Publicado 2018

Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the Lixi...

por Davies, Melanie J., Russell‐Jones, David, Barber, Thomas M., Lavalle‐González, Fernando J., Galstyan, Gagik R., Zhu, Dalong, Baxter, Mike, Dessapt‐Baradez, Cecile, McCrimmon, Rory J.
Publicado 2019

Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion

por Aschner, Pablo, Galstyan, Gagik, Yavuz, Dilek G., Litwak, Leon, Gonzalez-Galvez, Guillermo, Goldberg-Eliaschewitz, Freddy, Hafidh, Khadija, Djaballah, Khier, Tu, Shih-Te, Unnikrishnan, Ambika G., Khunti, Kamlesh
Publicado 2021

Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48‐week, multicenter, non‐randomized, parallel‐group, open‐labe...

por Galstyan, Gagik R., Valeeva, Farida V., Motkova, Svetlana I., Surkova, Elena V., Savelyeva, Larisa V., Rudina, Larisa M., Ramanathan, Krishnan, Sokareva, Ekaterina, Bondareva, Kristina, Shestakova, Marina V.
Publicado 2021